RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Zoladex
(United States) [Available]Synonyms :
Goserelin
Class :
Antineoplastics and GnRH Antagonist
Brand Name :
Zoladex
(United States) [Available]Synonyms :
Goserelin
Class :
Antineoplastics and GnRH Antagonist
Dosage Forms & Strengths
Implant
3.6mg
10.8mg
Monthly implant: 3.6 mg subcutaneously placed in the upper abdominal wall for every 28days
3-month implant: 10.8 mg subcutaneously placed in the upper abdominal wall for every 12week
Long term treatment intended for unless clinically inappropriate
3.6
mg
Subcutaneous (SC)
28
days
which is placed in the upper abdominal wall
Long term treatment intended for unless clinically inappropriate
3.6 mg subcutaneously placed in the upper abdominal wall for every 28days The maximum duration of the treatment is six months
when both drugs are combined, there may be increased toxicity of amiodarone by QTC interval
when both drugs are combined, there may be increased toxicity of anagrelide by QTC interval
when both drugs are combined, there may be increased toxicity of arsenic trioxide by QTC interval
when both drugs are combined, there may be increased toxicity of artemether by QTC interval
when both drugs are combined, there may be increased toxicity of citalopram by QTC interval
when both drugs are combined, there may be increased toxicity of disopyramide by QTC interval
when both drugs are combined, there may be an increase in qtc interval and toxicity of nilotinib
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval goser
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
QTc interval is increased both by lenvatinib and goserelin
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased QTC interval
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
osimertinib and goserelin, when used simultaneously, increase the QTc interval
One artificial decapeptide analogue of LHRH is goserelin.
When goserelin is taken in its biodegradable form, it effectively inhibits the release of pituitary gonadotropin.
Long-term suppression of serum testosterone and LH levels is the outcome.
Adverse drug reactions:
Frequency defined
>10%
Acne
Diarrhea
Breast atrophy
Flushing
Vaginitis
Hot flashes
Reduced libido
Mood swings
Depression
Sweating
Headache
Peripheral edema
Erectile dysfunction
Seborrhea
Tumor flare
Sexual dysfunction
Pain
UTI
1-10%
Nausea
Lethargy
Rash
COPD
Congestive heart failure
Cerebrovascular accident
Depression
Immune hypersensitivity reaction
Renal impairment
Headache
Frequency Not Defined
Asthenia
Breast changes
Cystitis
Dyspareunia
Dysmenorrhea
Hypercalcemia
Hirsutism
None
Contraindication:
Hypersensitivity
Caution:
Hypercalcemia
Women of childbearing potential and pregnancy
Tumor flare
Hyperglycemia and diabetes
Cardiovascular diseases
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Analog of gonadotropin-releasing hormone (LHRH); long-term goserelin stimulation suppresses serum levels of FSH and LH.
These trials used a single 250µg (aqueous solution) dosage of goserelin as well as one or more subcutaneous 3.6 mg depot doses.
Goserelin is available as a subcutaneous implant.
It is subcutaneous injection into the anterior abdominal wall preferably below the navel using a pre-filled syringe with a special delivery system (implant needle).
Administer at a 90-degree angle into the subcutaneous tissue of the lower abdomen.
Once inserted, the biodegradable implant slowly releases goserelin over time.
Patient information leaflet
Generic Name: Goserelin
Why do we use Goserelin?
Goserelin is indicated in combination with flutamide for the management of locally confined carcinoma of the prostate
It is used in palliative treatment of advanced carcinoma of the prostate.
It is also used in the treatment of advanced breast cancer in pre- and perimenopausal women.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
